Japan Clinical Trials Market Size & Outlook, 2023-2030
Japan clinical trials market, 2018-2030 (US$M)
Related Markets
Japan clinical trials market highlights
- The Japan clinical trials market generated a revenue of USD 1,948.7 million in 2023 and is expected to reach USD 3,229.8 million by 2030.
- The Japan market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, phase iii was the largest revenue generating phase in 2023.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
Clinical trials market data book summary
| Market revenue in 2023 | USD 1,948.7 million |
| Market revenue in 2030 | USD 3,229.8 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Thermo Fisher Scientific Inc, Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, PAREXEL, Wuxi AppTec Co Ltd, Labcorp Holdings Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Pfizer Inc, Caidya |
Other key industry trends
- In terms of revenue, Japan accounted for 2.4% of the global clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,675.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Trials Market Scope
Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 53.16% in 2023. Horizon Databook has segmented the Japan clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
In addition, the increasing number of pipeline drug candidates is boosting the R&D efforts required, favoring R&D outsourcing to CROs. The regulatory process is supportive of faster clinical trial approval. For instance, clinical trials can be started once the probable benefits are demonstrated by a relatively smaller number of clinical trials.
Market movement in the country has led a large number of pharmaceutical and medical device manufacturers to prefer CRO services to innovate new products, which is expected to contribute to market growth.
The acquisition will include the Japan & APAC (ex-China) 1 territory rights to the pipeline of Idorsia’s portfolio’s medicines with lead product PIVLAZ (clazosentan), commercially available in the market with fast-growing sales in Japan. Such efforts are expected to boost the market over the forecast period.
Reasons to subscribe to Japan clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan clinical trials market databook
-
Our clientele includes a mix of clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Japan clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan clinical trials market size, by phase, 2018-2030 (US$M)
Japan Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
